PHA-793887 is primarily utilized in research settings as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK2, CDK5, and CDK7. Its application is significant in studying cell cycle regulation and understanding the mechanisms of CDKs in cellular processes. Researchers employ it to investigate the role of CDKs in cancer development, as dysregulation of these kinases is often associated with tumor growth and progression. Additionally, PHA-793887 is used in preclinical studies to explore potential therapeutic strategies for targeting CDKs in various cancers. Its ability to inhibit CDK activity makes it a valuable tool for elucidating pathways involved in cell proliferation and apoptosis, contributing to the development of novel anticancer therapies.